News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Thrasos Therapeutics Initiates Phase 1 Clinical Trial for THR-184 in Acute Kidney Injury


9/13/2011 10:25:43 AM

MONTREAL--(BUSINESS WIRE)--Thrasos Innovation, Inc. today announced that it has initiated a Phase 1 clinical trial to study the safety and tolerability of THR-184, which the Company is developing for the treatment of Acute Kidney Injury (AKI) post-surgery. THR-184 is a proprietary small peptide that selectively activates key receptors of the bone morphogenetic protein (BMP) family responsible for cell and tissue protection, repair and regeneration.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES